DrugPatentWatch Database Preview
Erythromycin ethylsuccinate - Generic Drug Details
What are the generic sources for erythromycin ethylsuccinate and what is the scope of freedom to operate?
Erythromycin ethylsuccinate
is the generic ingredient in twelve branded drugs marketed by Arbor Pharms Llc, Ani Pharms Inc, Ross Labs, Pharmacia And Upjohn, Alpharma Us Pharms, Dista, Naska, Parke Davis, Pharmafair, Wyeth Ayerst, Arbor Pharms Inc, Barr, Mylan, and Alra, and is included in twenty-two NDAs. Additional information is available in the individual branded drug profile pages.There are one hundred and three drug master file entries for erythromycin ethylsuccinate. Four suppliers are listed for this compound.
Summary for erythromycin ethylsuccinate
| US Patents: | 0 |
| Tradenames: | 12 |
| Applicants: | 14 |
| NDAs: | 22 |
| Drug Master File Entries: | 103 |
| Suppliers / Packagers: | 4 |
| Bulk Api Vendors: | 31 |
| Patent Applications: | 8,797 |
| DailyMed Link: | erythromycin ethylsuccinate at DailyMed |
Pharmacology for erythromycin ethylsuccinate
| Drug Class | Macrolide Macrolide Antimicrobial |
| Physiological Effect | Decreased Sebaceous Gland Activity |
Medical Subject Heading (MeSH) Categories for erythromycin ethylsuccinate
Synonyms for erythromycin ethylsuccinate
| 1014KSJ86F |
| 12125-46-1 |
| 1264-62-6 |
| 1334-36-7 |
| 1386-36-3 |
| 2'-(Ethyl butanedioate)erythromycin |
| 22372-15-2 |
| 4-18-00-07416 (Beilstein Handbook Reference) |
| 4-O-[(2S,3R,4S,6R)-4-(dimethylamino)-2-[[(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2,10-di |
| 41342-53-4 |
| 68206-56-4 |
| 7121-45-1 |
| AB00051980_11 |
| AB00051980_12 |
| AC1L9FGS |
| AKOS008145410 |
| BDBM96262 |
| BRN 0077638 |
| BSPBio_001978 |
| C12796 |
| C43H75NO16 |
| CAS-1264-62-6 |
| CCG-40201 |
| CHEBI:31555 |
| CHEMBL1200688 |
| cid_443953 |
| CPD000058868 |
| CS-4434 |
| D01361 |
| DivK1c_000764 |
| DSSTox_CID_2993 |
| DSSTox_GSID_22993 |
| DSSTox_RID_76821 |
| DTXSID4022993 |
| E-Mycin E |
| E-Mycin-E |
| E.E.S |
| E.E.S 200 |
| E.E.S 400 |
| E.E.S. |
| E.E.S. (TN) |
| E.E.S. 200 |
| E.E.S. 400 |
| EES (Antiobiotic) |
| EES Granules |
| EINECS 215-033-8 |
| ERITHROMYCIN ETHYL SUCCINATE |
| ERY-PED |
| EryPed |
| Eryped (TN) |
| Erythrocin ethyl succinate |
| Erythrocin W (TN) |
| erythrocinethylsuccinate |
| Erythromycin 2'-(ethyl butanedioate) |
| Erythromycin 2'-(ethyl succinate) |
| Erythromycin A Ethylsuccinate |
| Erythromycin ethyl succinate |
| Erythromycin ethylsuccinate (JP17/USP) |
| Erythromycin ethylsuccinate [JAN] |
| Erythromycin ethylsuccinate [USP:JAN] |
| Erythromycin mono(ethyl succinate) (ester) |
| Erythromycin-ethyl succinate |
| Erythromycin, 2'-(ethyl butanedioate) |
| Erythromycin, ethyl succinate |
| Erythromycin, mono(ethyl succinate) |
| Erythromycin, mono(ethyl succinate) (ester) |
| erythromycin,mono(ethylsuccinate) |
| erythromycin,mono(ethylsuccinate)(ester) |
| Erythroped |
| Eyrthromycin Ethyl Succinate |
| HMS1923I21 |
| HMS2091D03 |
| HMS502G06 |
| HSDB 3075 |
| HY-B0957 |
| IDI1_000764 |
| KBio1_000764 |
| KBio2_001526 |
| KBio2_004094 |
| KBio2_006662 |
| KBio3_001198 |
| KBioGR_001171 |
| KBioSS_001526 |
| LMPK05000001 |
| LS-147492 |
| MCULE-3725545409 |
| MLS000028651 |
| MLS001074901 |
| MLS001076672 |
| MolPort-003-666-180 |
| NCGC00021382-03 |
| NCGC00183038-01 |
| NINDS_000764 |
| NSC-756758 |
| NSC756758 |
| NSYZCCDSJNWWJL-YXOIYICCSA-N |
| oxo-oxacyclotetradec-6-yl]oxy]-6-methyloxan-3-yl] 1-O-ethyl butanedioate |
| Pediamycin |
| PEDIAMYCIN 400 |
| Pharmakon1600-01500279 |
| s4060 |
| SAM002548941 |
| SBI-0051367.P003 |
| SCHEMBL18259 |
| SMR000058868 |
| SPBio_001045 |
| Spectrum_001046 |
| SPECTRUM1500279 |
| Spectrum2_000983 |
| Spectrum3_000419 |
| Spectrum4_000536 |
| Spectrum5_000668 |
| SR-05000001617 |
| SR-05000001617-1 |
| Succinic acid monoethyl ester monoester with erythromycin |
| Succinic acid, monoethyl ester, monoester with erythromycin |
| succinicacid,monoethylester,monoesterwitherythromycin |
| Tox21_113497 |
| UNII-1014KSJ86F |
| Wyamycin |
| Wyamycin E |
| ZINC169356230 |
US Patents and Regulatory Information for erythromycin ethylsuccinate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parke Davis | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | SUSPENSION;ORAL | 062231-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Naska | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | SUSPENSION;ORAL | 062674-001 | Mar 10, 1987 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Barr | ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL | erythromycin ethylsuccinate; sulfisoxazole acetyl | GRANULE;ORAL | 062759-001 | May 20, 1988 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Pharmafair | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | SUSPENSION;ORAL | 062558-001 | Mar 15, 1985 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Arbor Pharms Llc | E.E.S. 400 | erythromycin ethylsuccinate | TABLET;ORAL | 061905-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.